Innate and adaptive immune cells secrete different cytokines, which participate through distinct mechanisms in cell-mediated immunity and humoral immune responses. The aim of this study was to evaluate the immune response through analysis of type 1 (Th1), Th2, and Th17 cells in patients with epithelial ovarian cancer (EOC). Our study included 44 patients with EOC (study group) and 32 gynecological patients with no ovarian disease (control group). Fragments of ovarian tissue and blood samples were collected in both groups and aliquots of intracystic fluid and peritoneal fluid were recovered from the EOC patient group. Interleukin (IL)-2/IL-4/IL-6/IL-10/IL-17/tumor necrosis factor (TNF)-α/interferon (IFN)-γ levels were measured by cytometric bead array. Statistical analysis included chi-squared, Student t, Mann-Whitney, Kruskal-Wallis tests, and Cox regression model. Patients with EOC were associated with higher levels of TNF-α/IL-4/IL-6/IL-10 compared to the control group. Both IL-10 and TNF-α concentrations were higher in patients with stage III/IV EOC and also associated with higher levels of cancer antigen 125. Higher Th1-mediated immune response was observed when the cytoreduction was considered optimal. However, patients with EOC with unsatisfactory cytoreductive surgery and undifferentiated tumors were associated with higher concentrations of Th2 cytokines in the 4 sites studied. Higher IL-6/IL-10 and lower IFN-γ concentrations were also associated with a lower overall survival rate in patients with EOC. The EOC group presented a predominantly Th2 response and an immunosuppressant standard and had association between IL-6/IL-10/IFN-γ and prognosis.
PolverinoGParazziniFStellatoGScarfoneGCiprianiSBolisG. Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy. Gynecol Oncol. 2005;99(2):343–347.
3.
YigitRFigdorCGZusterzeelPLPotsJMTorensmaRMassugerLF. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer. 2011;47(12):1883–1889.
4.
MosmannTRCherwinskiHBondMWGiedlinMACoffmanRL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136(7):2348–2357.
5.
ZitvogelLTesniereAKroemerG. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715–727.
6.
KulbeHThompsonRWilsonJLThe inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007;67(2):585–592.
7.
EgbertsJHCloostersVNoackAAnti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008;68(5):1443–1450.
8.
YueFYDummerRGeertsenRInterleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer. 1997;71(4):630–637.
9.
TorresMPPonnusamyMPLakshmananIBatraSK. Immunopathogenesis of ovarian cancer. Minerva Med. 2009;100(5):385–400.
10.
NilssonMBLangleyRRFidlerIJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005;65(23):10794–10800.
11.
NelmsKKeeganADZamoranoJRyanJJPaulWE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701–738.
12.
KawakamiKKawakamiMPuriRK. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol. 2001;21(1-3):299–310.
13.
KioiMTakahashiSKawakamiMKawakamiKKreitmanRJPuriRK. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy. Cancer Res. 2005;65(18):8388–8396.
ZhangLConejo-GarciaJRKatsarosDIntratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–213.
16.
RaspolliniMRCastiglioneFRossi Degl'innocentiDTumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol. 2005;16(4):590–596.
17.
OuyangWKollsJKZhengY. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454–467.
18.
KryczekIBanerjeeMChengPPhenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141–1149.
19.
van NagellJRJr, PavlikEJ. Ovarian cancer screening. Clin Obstet Gynecol. 2012;55(1):43–51.
20.
BenedetJLBenderHJonesH 3rd, NganHYPecorelliS. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70(2):209–262.
21.
RustinGJTimmersPNelstropAComparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol. 2006;24(1):45–51.
22.
NowakMGlowackaESzpakowskiMProinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett. 2010;31(3):375–383.
23.
KavsakPALeeAHirteHYoungEGauldieJ. Cytokine elevations in acute coronary syndrome and ovarian cancer: a mechanism for the up-regulation of the acute phase proteins in these different disease etiologies. Clin Biochem. 2008;41(7-8):607–610.
24.
DaraiEDetchevRHugolDQuangNT. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod. 2003;18(8):1681–1685.
25.
HagemannTWilsonJBurkeFOvarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006;176(8):5023–5032.
26.
WangTNiuGKortylewskiMRegulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10(1):48–54.
27.
CarrTMAdairSJFinkMJHoganKT. Immunological profiling of a panel of human ovarian cancer cell lines. Cancer Immunol Immunother. 2008;57(1):31–42.
28.
BalkwillFCharlesKAMantovaniA. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7(3):211–217.
29.
SchuurhuisDHvan MontfoortNIoan-FacsinayAImmune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol. 2006;176(8):4573–4580.
30.
GavalasNGKaradimouADimopoulosMABamiasA.Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol. 2010;2010:791603.
31.
SchmelerKMVadhan-RajSRamirezPTA phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009;113(2):210–215.
32.
ScambiaGTestaUBenedetti PaniciPPrognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71(2):354–356.
33.
TempferCZeislerHSliutzGHaeuslerGHanzalEKainzC. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol. 1997;66(1):27–30.
34.
OffnerFAObristPStadlmannSIL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine. 1995;7(6):542–547.
35.
DuanZFosterRBellDASignal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006;12(17):5055–5063.
36.
ObataNHTamakoshiKShibataKKikkawaFTomodaY. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res. 1997;17(1A):337–342.
MahipalATeraiMBerdDTumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011;60(7):1039–1045.
39.
TeraiMTamuraYAlexeevVHuman interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother. 2009;58(8):1307–1317.
